Celcuity (CELC) recently released positive results from its phase 3 VIKTORIA-1 trial, which used its drug gedatolisib in combination with other therapies to treat patients with PIK3CA wildtype ...
Backlog in July rose to 8.8 months, up 0.4 months from the previous year, driven by data center and infrastructure projects Contractor confidence declined, with profit margin expectations at their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback